The US military kicked in $17m to support the Phase III development of AcelRx Pharmaceuticals Inc.'s ARX-04 and the most recently reported data for the fast-acting pain drug seem to show that it could meet the specialty customer's needs for the product.
The military did not require a single-arm, open-label clinical trial in the emergency room setting, but study is the closest...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
